Glucagon-like peptide-1 receptor activation and mental health: a drug-target mendelian randomization study.

Guoyi Yang, Stephen Burgess, C Mary Schooling

Abstract read

In one paragraph

Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Guoyi YangSchool of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. yanggy@connect.hku.hk.ORCID http://orcid.org/0000-0002-4387-386X

Stephen BurgessMRC Biostatistics Unit, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-5365-8760

C Mary SchoolingSchool of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Funding

American Heart Association (American Heart Association, Inc.) 26POST1560184Wellcome TrustWellcome Trust (Wellcome) 225790/Z/22/Z

6 · The paper itself

Abstract

Concerns have been raised about the psychiatric safety of glucagon-like peptide-1 receptor (GLP-1R) agonists, but trial evidence suggests that they ameliorate depressive symptoms. We aimed to assess the associations of GLP-1R activation with mental health well-being and the risk of mental health disorders and substance use disorders. We performed drug-target Mendelian randomization and colocalization analyses using the largest relevant genome-wide association studies and replicated in FinnGen. After correcting for multiple comparisons, genetically predicted lower body mass index (BMI) via GLP-1R activation was associated with a better well-being spectrum (0.06 standard deviation [95% confidence interval 0.03-0.08]), lower risk of major depressive disorder (odds ratio 0.82 [0.75-0.88]), and lower risk of bipolar disorder (odds ratio 0.61 [0.47-0.79]) per 1-kg/m

Indexed as

Bipolar DisorderGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsMajor Depressive DisorderBody Mass IndexGenome-Wide Association StudyHumansMendelian Randomization AnalysisPolymorphism, Single NucleotideGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor Agonists

Identifiers

PMID42443148

DOI10.1038/s41398-026-04244-7

PMCPMC13642936

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.